Introduction
============

Endometrial cancer (EC), referred to as uterine corpus endometrial cancer (UCEC), is one of the most common gynaecologic malignancy all over the world and most frequently occurs in postmenopausal women \[[@r1],[@r2]\]. Symptoms arising from UCEC included postmenopausal vaginal bleeding, enlarged uterus, low abdominal pain, and pelvic cramping, which forms the basis of clinical diagnosis \[[@r3],[@r4]\]. There were 569,847 newly registered cases and 311,365 deaths caused by corpus uteri cancer in 2018, causing a serious burden to public health, particularly to people in developing countries \[[@r5]\]. Precision medicine, powered by health record and genetic data of patients, refers to the concept that health care is individually tailored on the basis of a person's genes, lifestyle and environment. Advances in genomic sequencing has made precision medicine the main melody of current anti-cancer treatment and we attempted to seek reliable genetic changes from the aspect of alternative splicing (AS) to enhance the individualized prognosis prediction of UCEC patients \[[@r6]\].

Alternative splicing (AS) is crucial a mechanism by which the complexity of mammalian and viral proteom increased overwhelmingly \[[@r7],[@r8]\]. Through selective removal of introns and junction of exons, mRNA isoforms with diversified functions can be generated from a single gene \[[@r9],[@r10]\]. AS events occurred in cancer-related genes have significant impact on the progression of human cancers, which is evidenced by the fact that extensive studies reported a large number of AS events in multiple human cancers \[[@r11]--[@r13]\]. The occurrence of AS abides by a tissue specific and disease stage specific manner \[[@r9]\].

In UCEC, multiple splice variants of estrogen receptor (ER) and progesterone receptor (PR), two vital molecules that played important roles in the initiation and development of UCEC, were discovered as the results of AS \[[@r14]\]. These receptor variants have been reported to affect the carcinogenesis of UCEC with distinct functions \[[@r14]--[@r16]\]. Spliced variants discovered in other genes such as synuclein gamma also implicated the contribution of AS to the tumorigenesis of EC \[[@r17]\]. Convinced of the critical influence of AS events on the tumorigenesis of UCEC, we inferred that AS events might serve as novel prognostic marker for UCEC. Previous studies have indicated that one isoform of ERa: ERaD7 and YT521 exon6-retention mRNA were significantly correlated with the survival of UCEC patients \[[@r15],[@r18]\]. Nevertheless, more unknown AS events in UCEC awaits further excavation. Herein, we pursued the present study on systematically exploring the prognostic significance of AS events in UCEC based on RNA sequencing data in TCGA in order to find promising prognostic predictors for UCEC patients.

RESULTS
=======

A preview of survival-associated AS events in UCEC
--------------------------------------------------

In total, 28281 AS events from 8137 genes were detected from 506 UCEC patients. Number of AS events identified in seven AS types were recorded in [Table 1](#t1){ref-type="table"}. For the 28281 AS events from 8137 genes, ES was the predominant type with the maximum number of AS events (n=9744). The intersecting sets of genes and AS events were visualized by UpSet plot in [Figure 1](#f1){ref-type="fig"}, which indicated that one gene might possessed up to six types of AS. With respect to the relationship between AS events and OS of UCEC patients, a total of 2630 survival-associated AS events in 1752 genes were reported from the univariate Cox regression analysis (P\<0.05). The distribution of the 2630 survival-associated splicing events in seven AS types was listed in [Table 2](#t2){ref-type="table"}. We selected top significant survival-associated AS events (P\<0.001) to investigate the enrichment of these AS events in biological functions and pathways as well as the interaction network beneath them. The results showed that these significant survival-associated AS events were obviously clustered in biological processes including viral RNA genome replication, regulation of RNA splicing and spliceosomal complex assembly (P\<0.01). Top three pathways assembled by these AS events were snRNP Assembly, COPI-mediated anterograde transport and Insulin receptor recycling (P\<0.01) ([Table 3](#t3){ref-type="table"}) ([Figure 2](#f2){ref-type="fig"}). Molecular Complex Detection (MCODE) was used to screen the modules of the protein-to-protein network using the following parameters: degree cut-off = 2, node score cut-off = 0.2, k-core = 2, and maximum depth = 100 \[[@r19]--[@r21]\]. Protein-protein interaction network analysis from Metascape for these genes revealed these AS events were gathered in seven MCODE components ([Figure 3](#f3){ref-type="fig"}).

###### Summary of AS events in UCEC.

  --------------- --------------------- -----------------
  Splicing type   Number of AS events   Number of genes
  AA              2270                  1691
  AD              1877                  1386
  AP              4458                  1792
  AT              7796                  3411
  ES              9744                  4604
  ME              86                    85
  RI              2050                  1413
  Total           28281                 10380
  --------------- --------------------- -----------------

Note: AA: alternate acceptor; AD: alternate donor; AP: alternate promoter; AT: alternate terminator; ES: exon skip; ME: mutually exclusive exons; RI: retained intron.

![**UpSet plots of AS events in UCEC.** The horizontal axis and vertical axes represent number of genes in the interacting sets of one or multiple AS types and number of gens in each AS type, respectively. AA: alternate acceptor; AD: alternate donor; AP: alternate promoter; AT: alternate terminator; ES: exon skip; ME: mutually exclusive exons; RI: retained intron.](aging-11-101753-g001){#f1}

###### Survival-associated AS events from univariate Cox regression analysis.

  --------------- --------------------- -----------------
  Splicing type   Number of AS events   Number of genes
  AA              172                   164
  AD              170                   159
  AP              391                   227
  AT              793                   440
  ES              929                   796
  ME              11                    11
  RI              164                   149
  Total           2630                  1752
  --------------- --------------------- -----------------

Note: AA: alternate acceptor; AD: alternate donor; AP: alternate promoter; AT: alternate terminator; ES: exon skip; ME: mutually exclusive exons; RI: retained intron.

###### Pathway and process enrichment analysis for top significant survival-associated AS events.

  --------------- ------------------------- ------------------------------------------ ------- ------------- -------------- --------------
  GO              Category                  Description                                Count   \%            Log10(P)       Log10(q)
  CORUM:351       CORUM                     spliceosome                                17      14.04958678   -18.01041164   -13.69903928
  R-HSA-191859    Reactome Gene Sets        snRNP assembly                             7       5.785123967   -8.019420114   -4.986801354
  R-HSA-6807878   Reactome Gene Sets        COPI-mediated anterograde transport        7       5.785123967   -6.0016261     -3.032676419
  CORUM:3118      CORUM                     SMN1-SIP1-SNRP complex                     3       2.479338843   -5.565637629   -2.652205275
  R-HSA-77387     Reactome Gene Sets        insulin receptor recycling                 4       3.305785124   -5.020037464   -2.21381508
  R-HSA-382551    Reactome Gene Sets        transport of small molecules               13      10.74380165   -3.98898093    -1.462938404
  R-HSA-72649     Reactome Gene Sets        translation initiation complex formation   4       3.305785124   -3.622820626   -1.156546304
  GO:0039694      GO Biological Processes   viral RNA genome replication               3       2.479338843   -3.484731862   -1.070409087
  GO:0043484      GO Biological Processes   regulation of RNA splicing                 5       4.132231405   -3.177663215   -0.892370138
  GO:0000245      GO Biological Processes   spliceosomal complex assembly              4       3.305785124   -3.010155112   -0.785142581
  GO:0007005      GO Biological Processes   mitochondrion organization                 9       7.438016529   -2.780755792   -0.606103997
  GO:0015711      GO Biological Processes   organic anion transport                    8       6.611570248   -2.575952409   -0.422942539
  GO:0042273      GO Biological Processes   ribosomal large subunit biogenesis         3       2.479338843   -2.182984218   -0.107140303
  GO:0006281      GO Biological Processes   DNA repair                                 8       6.611570248   -2.070668634   -0.009716275
  GO:0002028      GO Biological Processes   regulation of sodium ion transport         3       2.479338843   -2.015633166   0
  --------------- ------------------------- ------------------------------------------ ------- ------------- -------------- --------------

Note: GO: gene ontology; CORUM: the comprehensive resource of mammalian protein complexes.

![**Network of enriched terms.** (**A**) Nodes in the network represent corresponding genes of top significant survival-associated AS events. One-to-one match between colors of the nodes and enrichment terms were labeled in the left. Nodes that share the same cluster ID are typically close to each other; (**B**) Nodes in the network represent corresponding genes of top significant survival-associated AS events. One-to-one match between colors of the nodes and P values were labeled in the left. Enrichment terms containing more nodes tend to have a more significant P value.](aging-11-101753-g002){#f2}

![**Protein-protein interaction network for top significant survival-associated AS events.** Nodes in the network represent corresponding genes of top significant survival-associated AS events. Gene that clustered in the same MCODE component was unified in one color.](aging-11-101753-g003){#f3}

PI models featured by AS events for UCEC
----------------------------------------

Top significant survival-associated AS events in univariate Cox regression analysis (P\<0.001) were considered as candidate AS events for the construction of PI models. Then, multivariate Cox regression analysis was performed to select component AS events for PI models from the 308 top significant survival-associated AS events. According to the results, 26 significant AS events (P\<0.05) from multivariate Cox regression analysis were reserved to build PI models of six AS types (AA, AD, AP, AT, ME and RI) ([Table 4](#t4){ref-type="table"}). Particularly, all the 26 splicing events were merged to construct a PI for all AS types. Distributions of PSI for component AS events and risk scores in each PI model were displayed in [Figure 4](#f4){ref-type="fig"}. The predicting efficiency of the seven PI models was assessed by tROC curves and Kaplan-Meier survival analysis. As illustrated by a panel of tROC curves in [Figure 5](#f5){ref-type="fig"}, PI-AT demonstrated the highest capacity of estimating the prognosis of UCEC patients with an AUC value of 0.758, followed by PI-RI with an AUC value of 0.719. We also used Kaplan-Meier survival analyses to appraise the prognosis-predicting ability of the seven PI models. UCEC patients were separated into low risk and high risk group according to the median values of PI. The results suggested that six of the seven PI models (AD, AP, AT, ME, RI and ALL) exhibited good performance in stratifying the prognosis of low risk and high risk group ([Figure 5](#f5){ref-type="fig"}). Survival time of UCEC patients in low risk group of six PI models (AD, AP, AT, ME, RI and ALL) was significantly prolonged compared to that of UCEC patients in high risk group (P\<0.001). According to the assessment from univariate and multivariate Cox regression analysis, four PI models including PI-AP, PI-AT, PI-ME and PI-RI figure prominently with superior independent prognosis-predicting value in both univariate and multivariate Cox regression analysis ([Table 5](#t5){ref-type="table"}). (all P\<0.05). For all PI models, high-risk UCEC patients were more inclined to suffer from advanced clinical progression than low-risk UCEC patients, which is especially obvious for grade classification of UCEC ([Table 6](#t6){ref-type="table"}).

###### Component AS events of PI models for AA, AD, AP, AT, ES, ME and RI.

  --------------- ------------- -------- ---------------- ----------- --------- -------------- ---------
  Splicing type   Gene symbol   AS ID    Exons            From exon   To exon   Hazard ratio   P-value
  AA              SHPRH         78032    31.1             30          31.2      0.516          \<0.001
  AA              CASK          88861    24.1             23          24.2      0.759          \<0.001
  AD              FBXL19        36205    8.2              8.1         9         1.030          0.004
  AD              SAT2          39030    5.2              5.1         6         1.112          0.007
  AD              TRO           89255    12.2:12.3        12.1        13        0.986          0.036
  AD              CSTF2         89611    12.2             12.1        13        0.001          \<0.001
  AP              ZC3H11A       9456     4                null        null      1.203          0.041
  AP              STK32C        13483    2                null        null      1.072          0.001
  AP              GRB2          43439    1                null        null      0.961          0.031
  AP              CRTC1         48500    2                null        null      3.785          0.004
  AP              ERCC1         50440    1                null        null      1.283          0.001
  AP              ESR1          78161    4                null        null      1.048          0.001
  AT              MAGI3         4271     23               null        null      0.913          0.018
  AT              TPM1          30982    13.2             null        null      1.153          \<0.001
  AT              ATP8B3        46544    29               null        null      0.978          0.001
  AT              MAST1         47878    14.2             null        null      1.015          0.027
  AT              SPAG16        57327    14               null        null      1.583          \<0.001
  AT              CBWD5         86498    17.2             null        null      1.051          0.002
  AT              OLFM1         88103    2                null        null      1.090          \<0.001
  ME              NSMF          193275   6\|7             4           9.2       1.075          0.035
  ME              GTF2H3        306194   10\|11           9           12        1.155          \<0.001
  RI              C11orf49      15609    14.2             14.1        14.3      1.021          0.045
  RI              ZNF276        38138    12.2             12.1        12.3      1.027          0.011
  RI              USP36         43917    17.2             17.1        17.3      0.039          0.006
  RI              NUDT18        82937    2.2              2.1         2.3       1.019          0.028
  RI              NAPRT1        85430    11.5:11.6:11.7   11.4        11.8      1.033          0.008
  --------------- ------------- -------- ---------------- ----------- --------- -------------- ---------

Note: AA: alternate acceptor; AD: alternate donor; AP: alternate promoter; AT: alternate terminator; ME: mutually exclusive exons; RI: retained intron; P values were calculated from multivariate Cox regression analysis.

![**Distribution of PSI values and risk scores in each PI model.** (**A**) distribution of PSI values in PI-AA model. (**B**) distribution of PSI values in PI-AD model. (**C**) distribution of PSI values in PI-AP model. (**D**) distribution of PSI values in PI-AT model. (**E**) Distribution of PSI values in PI-ME model. (**F**) Distribution of PSI values in PI-RI model. (**G**) Distribution of PSI values in PI-ALL model. The range of PSI values was annotated by a spectrum of colors from green to red; (**H**) Risk scores derived from significant survival-associated AS events in AA type. (**I**) Risk scores derived from significant survival-associated AS events in AD type. (**J**) Risk scores derived from significant survival-associated AS events in AP type. (**K**) Risk scores derived from significant survival-associated AS events in AT type. (**L**) Risk scores derived from significant survival-associated AS events in ME type. (**M**) Risk scores derived from significant survival-associated AS events in RI type. (**N**) Risk scores derived from significant survival-associated AS events in all types.](aging-11-101753-g004){#f4}

![**tROC curves and Kaplan-Meier survival curves seven PI models.** (**A**) tROC curve for PI-AA model (AUC=0.534). (**B**) tROC curve for PI-AD model (AUC=0.651). (**C**) tROC curve for PI-AP model (AUC=0.652). (**D**) tROC curve for PI-AT model (AUC=0.758). (**E**) tROC curve for PI-ME model (AUC=0.681). (**F**) tROC curve for PI-RI model (AUC=0.719). (**G**) tROC curve for PI-ALL model (AUC=0.678). (**H**) Kaplan-Meier survival curves for PI-AA model (P=0.1487). Average OS time in low and high risk group was 2762 and 4713 days, respectively. (**I**) Kaplan-Meier survival curves for PI-AD model (P\<0.001). Average OS time in low and high risk group was 5272 and 3219 days, respectively. (**J**) Kaplan-Meier survival curves for PI-AP model (P\<0.001). Average OS time in low and high risk group was 5165 and 3469 days, respectively. (**K**) Kaplan-Meier survival curves for PI-AT model (P\<0.001). Average OS time in low and high risk group was 5556 and 2511 days, respectively. (**L**) Kaplan-Meier survival curves for PI-ME model (P\<0.001). Average OS time in low and high risk group was 4569 and 3848 days, respectively. (**M**) Kaplan-Meier survival curves for PI-RI model (P\<0.001). Average OS time in low and high risk group was 3652 and 3957 days, respectively. (**N**) Kaplan-Meier survival curves for PI-ALL model (P\<0.001). Average OS time in low and high risk group was 4787 and 3594 days, respectively.](aging-11-101753-g005){#f5}

###### Univariate and Multivariate Cox regression analysis of clinical parameters and seven PI models in TCGA cohort of UCEC patients.

  ------------------- -------------- --------------------- -------------- --------------- ---------
  Clinical variable   Group          Univariate            Multivariate                   

  HR (95% CI)         P value        HR (95% CI)           P value                        

  Age                 \<60           2.247 (1.326-3.806)   0.003          1.722\          0.057
                                                                          (0.983-3.014)   

  ≥60                                                                                     

  Histological type   Endometrioid   2.413\                \<0.001        1.112\          0.590
                                     (1.590-3.663)                        (0.756-1.635)   

  Serous                                                                                  

  Grade               1-2            1.804\                0.009          1.203\          0.360
                                     (1.162-2.802)                        (0.810-1.785)   

  3                                                                                       

  Stage               I-II           3.918\                \<0.001        3.527\          \<0.001
                                     (2.568-5.978)                        (2.248-5.533)   

                      III                                                                 

  PI-AA               Low            0.734\                0.150          0.563\          0.031
                                     (0.481-1.119)                        (0.333-0.950)   

  High                                                                                    

  PI-AD               Low            2.446\                \<0.001        1.303\          0.310
                                     (1.570-3.813)                        (0.781-2.173)   

  High                                                                                    

  PI-AP               Low            2.237\                \<0.001        2.025\          0.003
                                     (1.428-.3.503)                       (1.270-3.229)   

  High                                                                                    

  PI-AT               Low            4.209\                \<0.001        2.102\          0.013
                                     (2.551-6.944)                        (1.170-3.776)   

  High                                                                                    

  PI-ME               Low            2.551\                \<0.001        2.058\          0.004
                                     (1.620-4.018)                        (1.261-3.359)   

  High                                                                                    

  PI-RI               Low            2.560\                \<0.001        2.052\          0.003
                                     (1.638-4.001)                        (1.283-3.282)   

  High                                                                                    

  PI-ALL              Low            2.057\                0.001          0.983\          0.953
                                     (1.330-3.181)                        (0.548-1.763)   

  High                                                                                    
  ------------------- -------------- --------------------- -------------- --------------- ---------

Note: AA: alternate acceptor; AD: alternate donor; AP: alternate promoter; AT: alternate terminator; ME: mutually exclusive exons; RI: retained intron.

###### Relationship between PI models and the progression of UCEC.

  ------------ --------------------------------- ---------------- ------------ --------- ---------
  Type of PI   Clinico-pathological parameters   Group of risk\   χ^2^         P value   
                                                 low % high %                            

  PI-AA        Grade                                                           4.577     0.032

  1-2          113 (27.3)                        90 (72.7)                               

  3            134 (31.3)                        158 (68.7)                              

  Stage                                                           0.627        0.429     

  I-II         186 (39.1)                        178 (60.9)                              

  III          67(17.0)                          75 (83.0)                               

  PI-AD        Grade                                                           18.409    \<0.001

               1-2                               126 (27.3)       77 (72.7)              

               3                                 124 (31.3)       168 (68.7)             

               Stage                                                           0.979     0.322

               I-II                              187 (39.1)       177 (60.9)             

               III                               66 (17.0)        76(83.0)               

  PI-AP        Grade                                                           1.583     0.208

               1-2                               109 (27.3)       94 (72.7)              

               3                                 140 (31.3)       152 (68.7)             

               Stage                                                           0.352     0.553

               I-II                              185 (39.1)       68 (60.9)              

               III                               179 (17.0)       74 (83.0)              

  PI-AT        Grade                                                           43.455    \<0.001

               1-2                               139 (27.3)       64 (72.7)              

               3                                 112 (31.3)       180 (68.7)             

               Stage                                                           20.715    \<0.001

               I-II                              205 (39.1)       159 (60.9)             

               III                               48 (17.0)        94 (83.0)              

  PI-ME        Grade                                                           26.660    \<0.001

               1-2                               132 (27.3)       71 (72.7)              

               3                                 121 (31.3)       171 (68.7)             

               Stage                                                           1.410     0.235

               I-II                              188 (39.1)       176 (60.9)             

               III                               65 (17.0)        77 (83.0)              

  PI-RI        Grade                                                           25.217    \<0.001

               1-2                               130 (27.3)       73 (72.7)              

               3                                 120 (31.3)       172(68.7)              

               Stage                                                           0.352     0.553

               I-II                              185 (39.1)       179(60.9)              

               III                               68 (17.0)        74 (83.0)              

  PI-ALL       Grade                                                           25.974    \<0.001

               1-2                               130 (27.3)       73 (72.7)              

               3                                 119 (31.3)       173 (68.7)             

               Stage                                                           6.618     0.010

               I-II                              195 (39.1)       169 (60.9)             

               III                               58(17.0)         84 (83.0)              
  ------------ --------------------------------- ---------------- ------------ --------- ---------

Note: AA: alternate acceptor; AD: alternate donor; AP: alternate promoter; AT: alternate terminator; ME: mutually exclusive exons; RI: retained intron.

Correlation network of splicing factor-related AS events and survival associated AS events
------------------------------------------------------------------------------------------

We downloaded information of 74 splicing factors and the corresponding splicing factor-related AS events from the SpliceAid2 database and TCGA. Results from univariate Cox regression analysis suggested that 16 splicing factor-related AS events were remarkably linked to the survival of UCEC patients ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The correlation between the 16 splicing factor-related AS events and 26 significant AS events from multivariate Cox regression analysis were calculated and significant correlations were presented as a correlation network in [Figure 6E](#f6){ref-type="fig"} (P\<0.05) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Blue nodes (n=16) and purple nodes (n=24) represented splicing factor-related AS events and significant AS events from multivariate Cox regression analysis, respectively. Positive and negative correlations between splicing events were marked as red lines (n=68) and green lines (n=64), respectively. We also conducted Kaplan-Meier survival analysis for the 12 splicing factors of the 16 splicing factor-related AS events after dividing UCEC patients according to the average expression value of the 12 splicing factors. We found that four splicing factors including RBM4, ESRP1, TRA2B and SRSF2 served as significant prognostic indicators for the worse survival of UCEC patients (P\<0.05) ([Figure 6A-D](#f6){ref-type="fig"}).

![**Kaplan-Meier survival curves for appraising the prognostic significance of splicing factors in UCEC and Correlation network**. (**A**) Kaplan-Meier survival curves for RBM4 (P=0.0083). (**B**) Kaplan-Meier survival curves for ESRP1 (P=0.0038). (**C**) Kaplan-Meier survival curves for TRA2B (P=0.0455). (**D**) Kaplan-Meier survival curves for SRSF2 (P=0.0212). (**E**) Correlation network between splicing factor-related AS events and significant survival-associated AS events. Blue nodes (n=16) and purple nodes (n=24) represented splicing factor-related AS events and significant AS events from multivariate Cox regression analysis, respectively. Positive and negative correlations between splicing events were marked as red lines (n=68) and green lines (n=64), respectively.](aging-11-101753-g006){#f6}

DISCUSSION
==========

Existing risk stratification for UCEC patients based on morphological classification had limited power in predicting the overall survival conditions of UCEC patients and it remained unsolved to find effective prognostic indicator for UCEC patients. Accumulated evidence suggested that AS exerted vast influence on the biological events of human cancers \[[@r22]--[@r24]\], which enlightened us that the aberrant AS profiles in UCEC may provide valuable prognostic information. Although multiple splice variants of molecules such as ER and PR have been reported in previous studies to participate in the pathogenesis of UCEC, there lacks systematic and comprehensive analysis of the prognostic significance of AS profiling landscape for UCEC.

The present study is the first to investigate global pattern of survival-associated AS events in UCEC using TCGA data. Results from univariate Cox regression analysis revealed that thousands of AS events were associated with the survival of UCEC patients (P\<0.05). Subsequent functional annotation for genes corresponding to the significant survival-associated AS events in UCEC (P\<0.001) indicated that these genes were mainly involved in biological processes and pathways including viral RNA genome replication, regulation of RNA splicing, spliceosomal complex assembly, snRNP Assembly, COPI-mediated anterograde transport and Insulin receptor recycling. AS events generated from these genes might affect the initiation and development of UCEC through interfere with the above biological processes and pathways.

Bioinformatics analysis of the significant survival-associated AS events in UCEC is one of the highlights of our research. The most striking clinical implication of the present study was that we constructed PI models with noticeable predicting power for overall survival of UCEC patients. Six PI models exhibited significant ability in prognosing overall survival time of UCEC patients with PI-AT performing best (AUC=0.758). More encouragingly, univariate and multivariate Cox regression analysis proved four of the PI models including PI-AP, PI-AT, PI-ME and PI-RI as independent prognostic factors for UCEC. Prior to our studies, several researchers have developed prognostic models for UCEC based on other genomic signatures. Zhou M et al. have devised a lncRNA-focus expression signature for survival prediction in UCEC, which achieved excellent prognostic performance (AUC=0.887) \[[@r25]\]. The high AUC value in the study of Zhou M et al. was derived from a validation cohort of 151 UCEC patients while 506 UCEC patients in our study were designated as validation groups for PI. AUC values of a six-gene signature proposed by Wang Y et al. and a nine-gene prognostic model devised by Ying J et al. reached 0.787 and 0.82, respectively \[[@r26],[@r27]\]. The difference values between these two gene-expression signatures and PIs in our study were within the range of ±0.1, which indicated that the prediction efficiency of PIs in this study were comparable with gene-expression models. In the current study, UCEC cases enrolled in the prognostic analysis were restricted to those whose OS time exceeded 90 days and the validation cohorts were composed of 506 UCEC patients from TCGA, which is different from previous study with similar works. It is understandable that a certain amount of error was inevitable due to the inclusion criteria of patients with prognostic data and heterogeneity of validation cohort. Results in our study offered a novel visual angle for the precision medicine of UCEC patients and the molecular mechanism of tumorigenesis of UCEC. Evaluation results from tROC curves and Kaplan-Meier survival curves proved that building PI models based on survival --associated AS events was a feasible way to stratify UCEC patients into risk groups of different survival outcome.

It is well known that AS may introduce nonsense-mediated mRNA decay, truncated protein and increased or decreased miRNA binding sites, eventually changing the quality and quantity of protein product. Additionally, splicing events in untranslated regions or non-coding RNAs might lead to abnormal gene function \[[@r28]\]. Cancer-specific mRNA transcripts may affect the formation and progression of human cancers via activating oncogenes or inhibiting tumour suppressor genes \[[@r29]\]. Splice-switching of MYO1B into an oncogenic isoform drove gliomagenesis \[[@r30]\]. Presence or absence of exon7 in two splicing isoforms of MBNL1 conveyed opposite phenotypical implications of cancer \[[@r31]\]. Two splicing isoforms of ZNF148 exerted mutual antagonistic effect to each other on the biological activities of colorectal cancer \[[@r32]\]. Throughout the 26 corresponding genes of component AS events for PI models, four genes were closely associated with UCEC. In the study of Wong YF et al., OLFM1 was found to display significant down-regulation in endometrial cancer of Hong Kong Chinese women \[[@r33]\]. Oestrogen receptor α (ESR1) has great impact on the susceptibility and prognosis of endometrial cancer \[[@r34]\]. Latest research discovered that five adjacent tag single-nucleotide polymorphisms at the 5' end of ESR1 denoted lower risk of UCEC \[[@r35]\]. Significant correlation was established between single nucleotide polymorphisms of ERCC1 and chemosensitivity of UCEC in the study conducted by Chen L et al. \[[@r36]\]. Elevated GRB2 was engaged in oncogenic events of UCEC triggered by insulin \[[@r37]\]. Apart from the four genes, other genes such as FBXL19, CSTF2, ZC3H11A, CRTC1 and MAGI3 influenced the formation and progression of human cancers with either carcinogenic or tumor-suppressive function \[[@r38]--[@r42]\]. Although none of the corresponding AS events of the 26 genes was reported in UCEC, it is conjectured that loss-of function for the tumor suppressor gene or gain-of-function and retain-of-function for the oncogene induced by AS may connect the 26 component AS events in PI models to the cancer biology of UCEC.

As critical regulators of splicing events, the prognostic significance of splicing factors and the correlation between splicing factor-related AS events and survival-associated AS events are also worthy of exploration. Correlation network in this study depicted the complicated interactions between splicing factor-related AS events and survival-associated AS events. Both positive and negative correlations were observed between one splicing factor-related AS event and multiple survival-associated AS events; or one survival associated AS event and multiple splicing factor related AS events. For example, SERBP1_AA_3354 was negatively correlated with HNRNPA1_AA_22145 and was positively correlated with HNRNPC_ES_26552. We speculated that splicing factors might execute diversified regulatory functions in mediating AS events of UCEC. Moreover, assessment from Kaplan-Meier survival analysis indicated that four splicing factors including SRSF2, TRA2B, ESPR1 and RBM4 were all associated with the worse survival of UCEC patients. Of note, SRSF2 was linked with poor survival of patients with myelodysplastic syndromes and the frequent mutation of SRSF2 could induce oncogenesis in hematopoietic cells through activating a cascade of alternative splicing \[[@r43]\]. Expression of TRA2B served as independent prognostic factor for the worse progression-free survival of UCEC patients in the study of Ouyang YQ1 et al. \[[@r44]\], which were in concordance with our results. However, the prognostic significance of ESRP1 and RBM4 in this study was conflicting with documents in previous studies. ESRP1 is a kind of epithelial cell-specific epithelial cell-specific alternative splicing controller with involvement in epithelial--mesenchymal transition (EMT) \[[@r45],[@r46]\]. ESRP1 could suppress tumorigenic potential in various cancers including colorectal cancer, pancreatic cancer and ovarian cancer \[[@r47]--[@r49]\]. Similarly, RBM4 was reported to inhibit tumor progression via specifically controlling splicing related to the apoptosis, proliferation, and migration of cancer cells \[[@r50]\]. Whether the expression of ESRP1 and RBM4 indicated good or poor clinical outcome of UCEC patients require further investigations in future studies.

Although PI models with impressive predicting power were produced in this study, limitations of the present research should also be pointed out. The prediction efficiency of PIs in this study was not the best among all prognostic models to date. Functional annotation of the genes corresponding to significant survival-associated AS events were theoretical analysis based on public databases. The regulatory network was constructed on the correlations calculated between PSI values of splicing factor-related AS events and survival-associated AS events. Experiments were warranted in future studies to validate the functional role of survival-associated AS events in UCEC and the stimulating or inhibitive influence of splicing factors on AS events.

In conclusion, we identified PI models based on survival-associated AS events for UCEC with preferable prognosis-predicting ability. Findings in this study were anticipated to provide novel options for selecting reliable prognostic indicators for UCEC patients. Furthermore, the correlation network between splicing factor-related AS events and survival-associated AS events may deepen the understanding of the carcinogenesis of UCEC.

MATERIALS AND METHODS
=====================

Process of AS data curation
---------------------------

TCGA data portal (<https://portal.gdc.cancer.gov/>) provided the RNA sequencing data of UCEC cohorts. Analysis of mRNA splicing profiles in UCEC was conducted with the aid of SpliceSeq \[[@r51]\], a java program that explicitly quantifies RNA-Seq reads and identifies its possible functional changes as a consequence of AS in the context of transcript splice graphs. We downloaded the percent spliced in (PSI) value for seven types of AS events: Exon Skip (ES), Mutually Exclusive Exons (ME), Retained Intron (RI), Alternate Promoter (AP), Alternate Terminator (AT), Alternate Donor site (AD) and Alternate Acceptor site (AA) to quantify AS events in UCEC. PSI value is a commonly used ratio for the scoring of AS events from zero to one.

A preview of survival-associated AS events in UCEC
--------------------------------------------------

A total of 506 EC patients were included in this study and the overall survival (OS) of the 506 included EC patients were at least 90 days. Since it would be extremely intricate to illustrate the relationship between five or more interactive sets, we used UpSetR (version 1.3.3) \[[@r52]\] rather than Venn diagram to present the intersections between seven types of AS. Interactive sets among the seven types of AS events were visualized by UpSet plot. Based on the median cut of each parameter, these patients were divided into two groups. Univariate Cox regression analysis was conducted to identify survival-associated AS events (P\<0.05). Functional enrichment analysis and gene network of top significant survival-associated AS genes (P\<0.001) in UCEC were imported from Metascape, (<http://metascape.org>), an online tool that incorporates resources including KEGG Pathway, GO Biological Processes, Reactome Pathway Database, Canonical Pathways and CORUM to provide functional annotation for genes. Significant terms met the criteria of P value \< 0.01 and the number of enriched genes ≥ 3.

PI models featured by AS events for UCEC
----------------------------------------

Multivariate Cox regression analysis was applied to top significant survival-associated AS events (P\<0.001) selected from univariate Cox regression analysis in each AS type for further evaluation of the prognostic value of AS events in UCEC. AS events with P \<0.05 from multivariate Cox regression analysis were retained to construct prognostic index (PI) for the corresponding AS type, which was calculated from the following formula: PI=$\sum\limits_{i}^{n}{PSIi*\beta i}$ (β means the regression coefficient). To compare the efficiency of PI models for each AS type, survival ROC package (version 1.0.3) in R (version 3.3.0) that enables time-dependent receiver operating curves (tROC) estimation to accommodate censored data \[[@r53]\] was employed to calculate area under the curve (AUC) value for the tROC curves of each PI model. Kaplan-Meier survival curves were also used to compare the prognostic ability of prediction models. P values reported from all analyses were two-sided. To examine the independence between PI models and important clinical features, we performed univariate and multivariate Cox regression analysis to compare the hazard ratio (HRs) of PI models and important clinical features for UCEC. Furthermore, the relationship between PI models and clinical progression of UCEC was calculated through Chi square test in SPSS v.22.0.

Correlation network of splicing factor-related AS events and survival associated AS events
------------------------------------------------------------------------------------------

Splicing factors played indispensable role in regulating splicing events \[[@r54]\]. In this study, we dived deeper into the underlying molecular mechanism of AS events in UCEC through exploring the correlation network of splicing factor-related AS events and survival associated AS events. We obtained the information of splicing factors from SpliceAid2 ([www.introni.it/spliceaid.html](http://www.introni.it/spliceaid.html)) and downloaded the level 3 mRNA-seq expression data of the splicing factors from TCGA data portal. Considering the rationality of transcripts per million (TPM) format in the interpretation of RNA-seq data \[[@r55]\], primitive count values were converted into TPM. We conducted univariate Cox regression analysis to assess the association between OS of UCEC patients and PSI of splicing factor-related AS events in TCGA. Whether significant correlation existed between PSI of survival-associated splicing factor-related AS events (P\<0.05) and distinct AS events from multivariate Cox regression analysis (P\<0.05) were judged by Spearman correlation test. Interactions between survival-associated splicing factor-related AS events and distinct AS events from multivariate Cox regression analysis were displayed in the form of correlation network by Cytoscape (version 3.5.0). Adjusted P values were considered significant when less than 0.05.

Statistical analysis
--------------------

Statistical analysis for this study has been detailed in previous study \[[@r56]\].
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